FDA Clearance Tracker · P130029-S007
Fluency Plus Endovascular Stent Graft
Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Oct 5, 2017
Approved
Time to decision
178 days
Received Apr 10, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P130029-S007
- Device name
- Fluency Plus Endovascular Stent Graft
- Applicant
- Bard Peripheral Vascular, Inc.
- Applicant location
- Tempe, AZ
- Received
- Apr 10, 2017
- Decided
- Oct 5, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P130029
Device type
- Device type
- System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for an update to the labeling to include the 24-month data on patients enrolled in the clinical study.
Source documents
Other decisions for Bard Peripheral Vascular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250050 · Decided Sep 25, 2026 · 303 days after receipt
Device type: SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS (MIR) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.